SCHEMBL23717328

SCHEMBL23717328

CCc1ccc(OC2CC2)c(OC)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.53
SIGMAR1 Q99720 1/20 0.49
CA2 P00918 5/20 0.48
PDE4B Q07343 4/20 0.46
PDE4A P27815 3/20 0.46
PDE4C Q08493 2/20 0.46
PDE4D Q08499 2/20 0.46
PTGS2 P35354 1/20 0.44
MAPK1 P28482 1/20 0.43
KDM4E B2RXH2 1/20 0.43
ATM Q13315 1/20 0.43
CA1 P00915 4/20 0.43
CA9 Q16790 4/20 0.43
CA12 O43570 3/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC2 Q92769 1/20 0.43
CALM1 P0DP23 1/20 0.43
ALDH1A1 P00352 1/20 0.42
PPARG P37231 1/20 0.42
PPARD Q03181 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13111720 0.93 RECQL (0.61) RECQLSIGMAR1CA2PDE4BPDE4A
SCHEMBL3976102 0.87 PDE4B (0.57) RECQLPDE4BPDE4APDE4CPDE4D
SCHEMBL31428 0.81 CA2 (0.71) SIGMAR1CA2PTGS2KDM4EATM
SCHEMBL31275634 0.81 CA2 (0.71) SIGMAR1CA2PTGS2KDM4EATM
SCHEMBL16533505 0.80 RECQL (0.51) RECQLCA2PDE4BPDE4APDE4C
Nitrous Acid SCHEMBL7214855 0.79 PDE4B (0.54) RECQLPDE4BPDE4APDE4CPDE4D
SCHEMBL15026756 0.79 TRPA1 (0.50) PDE4BMAPK1KDM4EALDH1A1LMNA
Ammonia Solution, Strong SCHEMBL266403 0.79 CA2 (0.68) SIGMAR1CA2PTGS2KDM4EATM
Water SCHEMBL8587595 0.79 CA2 (0.68) SIGMAR1CA2PTGS2KDM4EATM
SCHEMBL134754 0.79 RECQL (0.67) RECQLCA2PDE4BPDE4APDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11420976-B2 Heterocyclic compounds as anti-viral agents ENANTA PHARMACEUTICALS, INC. (US) 2022-08-23 US disclosed
US-20220119398-A1 HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS ENANTA PHARMACEUTICALS, INC. 2022-04-21 US disclosed
US-20210238188-A1 HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS ENANTA PHARMACEUTICALS, INC. 2021-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210238188-A1 HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS VIP, ACE, FURIN RECQL 1646/4885SIGMAR1 4225/4885CA2 1277/4885
US-20220119398-A1 HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS VIP, ACE, FURIN RECQL 1646/4885SIGMAR1 4225/4885CA2 1277/4885
US-11420976-B2 Heterocyclic compounds as anti-viral agents VIP, ACE, FURIN RECQL 1646/4885SIGMAR1 4225/4885CA2 1277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.